Aldeyra Therapeutics, Inc. - ALDX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Perceptive Advisors LLC | 7.0% | 4,185,632 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Joseph Edelman | 7.0% | 4,185,632 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Perceptive Life Sciences Master Fund, Ltd. | 7.0% | 4,185,632 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Perceptive Advisors LLC | 8.7% | 5,222,311 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Joseph Edelman | 8.7% | 5,222,311 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Perceptive Life Sciences Master Fund, Ltd. | 8.7% | 5,222,311 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.